Replimune Group (NASDAQ:REPL) Stock Jumps 5.3% – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares were up 5.3% during mid-day trading on Monday. The company traded as high as $12.14 and last traded at $12.0640. Approximately 201,064 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 4,305,646 shares. The stock had previously closed at $11.46.

Wall Street Analyst Weigh In

A number of research firms have commented on REPL. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. JPMorgan Chase & Co. raised their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, August 7th. Finally, BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Replimune Group Price Performance

The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The stock has a fifty day simple moving average of $13.53 and a two-hundred day simple moving average of $9.88. The company has a market cap of $1.16 billion, a PE ratio of -3.92 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, equities analysts predict that Replimune Group, Inc. will post -2.82 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer owned 99,425 shares in the company, valued at $1,289,542.25. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the sale, the chief executive officer owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 79,124 shares of company stock worth $1,038,364. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. bought a new position in shares of Replimune Group in the 2nd quarter valued at about $15,332,000. WINTON GROUP Ltd acquired a new stake in shares of Replimune Group in the second quarter valued at approximately $115,000. Engineers Gate Manager LP lifted its stake in Replimune Group by 15.0% in the 2nd quarter. Engineers Gate Manager LP now owns 172,998 shares of the company’s stock valued at $1,915,000 after purchasing an additional 22,504 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Replimune Group in the second quarter worth $151,000. Finally, Squarepoint Ops LLC acquired a new position in Replimune Group in the second quarter valued at $1,454,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.